Posted by Michael Wonder on 06 May 2025
Ichnos Glenmark Innovation receives US FDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma
5 May 2025 - IGI, today announced that the US FDA has granted fast track designation for ISB 2001.
This important designation was granted for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
